Special use-results survey of ENAROY Tablets (long-term use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210549

Enrollment

1500

Registered

2022-01-07

Start date

2022-03-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia associated with CKD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients using Enaroy for the first time for nephrogenic anemia (2) Patients must provide informed consent before the start

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
-Incidence of onset of thromboembolism -Incidence of onset of hypertension -Incidence of cardiovascular events (excluding thromboembolism) -Incidence of onset of retinal hemorrhage -Incidence of onset of malignant tumor -Incidence of progressed disease in patients with autosomal dominant polycystic kidney disease (ADPKD)	—

Contacts

Public ContactPatient Safety and Pharmacovigilance Dept.

Shionogi & Co., Ltd.

DL_pms-pharma@shionogi.co.jp+81-80-1054-2168

Outcome results